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Abstract: Recent genomic studies have demonstrated that fungi can possess gene clusters 
encoding for the production of previously unobserved secondary metabolites. Activation of 
these attenuated or silenced genes to obtain either improved titers of known compounds or 
new ones altogether has been a subject of considerable interest. In our efforts to discover new 
chemotypes that are effective against infectious diseases, including malaria and   
methicillin-resistant  Staphylococcus aureus (MRSA), we have isolated a strain of marine 
fungus,  Leucostoma persoonii, that produces bioactive cytosporones. Epigenetic modifiers 
employed to activate secondary metabolite genes resulted in enhanced production of known 
cytosporones B (1, 360%), C (2, 580%) and E (3, 890%), as well as the production of the 
previously undescribed cytosporone R (4). Cytosporone E was the most bioactive, displaying 
an IC90 of 13 µM toward Plasmodium falciparum, with A549 cytotoxicity IC90 of 437 µM, 
representing a 90% inhibition therapeutic index (TI90 = IC90 A459/IC90 P. falciparum) of 
33. In addition, cytosporone E was active against MRSA with a minimal inhibitory 
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concentration (MIC) of 72 µM and inhibition of MRSA biofilm at roughly half that value 
(minimum biofilm eradication counts, MBEC90, was found to be 39 µM). 
Keywords: epigenetics; fungus; mangrove; MRSA; malaria 
 
1. Introduction 
After coral reefs, mangrove communities are the most important ecosystem in the marine 
environment in terms of productivity and sustained tertiary yield. A study of over 150 species of fish 
demonstrated that the coral reefs near mangroves contained on average twice as much biomass as  
the reefs not near this niche [1]. The mangrove microenvironment is demanding of plants, as well  
as associated organisms living on or within their tissues, due to, for example, frequent variation of 
salinity, temperature and moisture. In addition, predation pressure is intense in these high-biodiversity 
systems. Mangrove tissues are replete with endophytic bacteria and fungi, and chemical investigations 
of these microbes have documented diverse bioactive natural products [2–10]. In our efforts to isolate 
antimalarial compounds from Floridian mangrove endophytes, we isolated a strain of the endophytic 
fungus Leucostoma persoonii from red mangrove, Rhizophora mangle, that showed moderate activity 
against malaria. We subsequently tested the extract against a variety of disease targets and found 
promising activity against a highly resistant methicillin-resistant Staphylococcus aureus (MRSA). Based 
on recent results using epigenetic modifications in fungi to produce new bioactive compounds [11–13], we 
experimented with small molecule epigenetic modifiers to enhance production of secondary metabolites in 
our fungal isolate. We report here conditions for the production of enhanced levels of known cytosporones 
B (1), C (2), and E (3), as well as a previously uncharacterized cytosporone [14–17] cytosporone R (4) 
(Figure 1).  
Figure 1. Structures of the cytosporones (1–4). 
 
2. Results and Discussion 
2.1. Fungal Isolation and Identification 
Leucostoma persoonii was isolated from red mangrove, Rhizophora mangle, branch tissues obtained 
from the Florida Everglades in the summer of 2010. In the field, a portion of the branch was surface 
sterilized then shavings of the bark were placed onto saline cornmeal agar. The plates were incubated for 
3 days prior to colony selection and purification of fungal isolates. L. persoonii was found as a slow Mar. Drugs 2012, 10                 
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growing tan/yellow filament. Analysis of the 18S ribosome DNA by BLAST database screening 
provided a 99% match to L. persoonii. 
2.2. Malaria Screening 
Mangrove endophytes isolated as described above were subject to small-scale cultivation on 
Sabouraud dextrose agar (SDA), freeze dried, then extracted with methanol. Extracts at a concentration 
of 30 mg/mL were screened in a luciferase-reporter Plasmodium falciparum assay [18]. The L. persoonii 
extract demonstrated >50% inhibition at 50 µg/mL and was therefore selected for scale-up cultivation 
and bioassay-guided isolation studies. 
2.3. Antibiotic Screening 
Concomitant with malaria screening, aliquots of fungal extracts were applied to 6 mm cotton disks at 
0.1 mg/disk, then the disks subsequently placed on MRSA-inoculated agar. After 24 hour growth, the  
L. persoonii crude extract displayed a 12 mm diameter (disk plus clear zone) zone of inhibition (ZOI). 
This strain of MRSA has been found to be broadly resistant to a variety of antimicrobials including: 
methicillin, centhromycin, azithromycin, erythromycin, clindamycin, ampicillin, chloramphenicol, 
gentamicin, tetracycline, ciprofloxacin; as well as intermediary resistance to daptomycin, linezolid and 
vancomycin. Any zone of inhibition past 10 mm at this level, against this strain, is selected for further 
investigation as it is considerably better than existing antibiotic agents.  
2.4. Isolation of Active Compounds 
Plugs of SDA containing L. persoonii mycelia were removed and used to inoculate 12 × 400 mL 
Sabouraud dextrose broth (SDB). Mature cultures were frozen, then freeze dried and extracted 3× with 
methanol, yielding 1.30 g of crude extract. The residue was subjected to normal phase MPLC yielding 
6 fractions: A (632 mg), B (24 mg), C (84 mg), D (105 mg), E (248 mg), F (137 mg). These fractions 
were screened against MRSA and fraction B was found to be active with a 16 mm ZOI. It was further 
separated on reverse phase HPLC to afford pure cytosporones B (1, 1.1 mg), C (2, 0.5 mg) and E (3, 
1.9 mg). The compounds were identified by comparison of their mass and 
1H and 
13C NMR spectra to 
those previously reported [14].  
2.5. Bioactivity of Cytosporones B, C and E 
Screening against a highly resistant MRSA strain (USA100) established (Table 1) minimum inhibitory 
concentration (MIC), minimum bactericidal counts (MBC) and minimum biofilm eradication 
concentration (MBEC). At MIC, cytosporone B (1) demonstrated a 4.2-fold reduction in bacterial viability 
and at twice the MIC, resulted in complete killing of the bacteria. Furthermore, at MIC, a 2-fold 
reduction in biofilm formation was observed, and at twice the MIC, 168-fold reduction occurred. At 
higher concentrations, it appears strongly active toward biofilms, which is uncommon for antibiotics; 
however, cytosporone B is cytotoxic toward A549 cells (TI90 = IC90 A549/MIC90 = 6). Cytosporone C 
(2) was found to be inactive against MRSA at low µM doses and thus was not tested further.  
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Table 1. Summary of activity against methicillin-resistant Staphylococcus aureus (MRSA) 
USA100 and cytotoxicity of 1–3. 
Compound 
MRSA (µM)  A549 (µM) 
MIC MBC90 MBEC90 IC50 IC90 
Cytosporone B (1) 78  93  110  170  190 
Cytosporone C (2) >358
  NT 
a  NT 690  840 
Cytosporone E (3) 72  45
  39 280  440 
a NT: Not tested. 
Cytosporone E (3) was equipotent against USA100 and methicillin-sensitive S. aureus (MSSA) 
strains (72 µM), indicating the intrinsic drug resistant properties of MRSA strains are not helpful in 
resisting the action of this cytosporone. In effect, the target of the compound is something that the 
broadly drug resistant strains have not encountered before and suggestive that there is less likelihood that 
MRSA strains would develop resistance to it over time. In addition, at MIC, it resulted in >5000-fold 
reduction in bacterial viability, indicating it is strongly bactericidal, and not just bacteriostatic. The 
cytosporone E MBC90 is significantly below its MIC, further demonstrating developmental potential. 
Finally, the MBEC assay showed a 183-fold reduction in bacterial viability at MIC, demonstrating a 
particularly potent activity for this ultra-resistant strain of MRSA. Cytosporone E is also cytotoxic, but 
reasonably selective for bacteria relative to mammalian cells (TI90 = 10). 
Cytosporone B (1) and C (2) were inactive toward Plasmodium falciparum at the levels tested (up 
to 10 µg/mL). Cytosporone E (3), however, displayed an IC90 of 13 µM, which represents significant 
selectivity (TI90 = 33) for a moderately potent antimalarial drug.  
2.6. Epigenetics Studies 
The bioactivity profile of the cytosporones stimulated our interest in titer improvement and 
generation of additional derivatives, studies we chose to investigate using recently described epigenetic 
modification [11–13]. First, histone deacetylase (HDAC) and DNA methyltransferase (DNMT) 
inhibitors were employed in dose-response experiments in a 21-day incubation period. Using sodium 
butyrate as an HDAC inhibitor and 5-azacytidine as a DNMT inhibitor, bioassay results (Figure 2A) 
revealed the maximal Kirby-Bauer ZOI against USA100 MRSA were obtained using 50 µM DNMT 
inhibitor and 100 µM HDAC inhibitor. Subsequent time-course experiments, using the previously 
identified optimal inhibitor concentrations, indicated that the HDAC-inhibited culture exhibited maximal 
activity as early as week one, while the DNMT-inhibited culture and control required three weeks to 
achieve maximal activity (Figure 2B). Interestingly, experiments in which we combined the DNMT and 
HDAC inhibitors produced inconsistent results, with some replicate cultures more active and others 
inactive. Overall, the best experimental conditions required the HDAC inhibitor and the incubation time 
of two weeks. 
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Figure 2. (A) Average of triplicate zone of inhibition (ZOI) determinations against MRSA 
for the crude methanol extract at each concentration of epigenetic modifier; (B) Average of 
triplicate ZOI determinations against MRSA for the crude extract at each time point of 
incubation. The sterile disks measure 6 mm, thus a result of 6 mm indicates no inhibition at 
that concentration.  
 
(A) (B) 
LC/MS analyses of the culture extracts were found to corroborate the MRSA activity profiles in all 
cases (Figure 3). For example, in the dose-response experiment for the DNMT inhibitor, several peaks, 
including those with masses matching cytosporones B (1) and E (3), in the highlighted region, boast 
greater areas at the 50 µM concentration versus the others. In addition, certain peaks appear to be 
present in the chromatograms from the 50 and 100 µM DNMT inhibitor that are absent at the other 
concentrations. This indicates the presence of potential new compounds produced only by the addition 
of the epigenetic modifier in the fermentation. 
Figure 3. Overlay of LC/MS total ion chromatograms (TIC) from each concentration of 
crude extracts of DNA methyltransferase (DNMT)-inhibited cultures. Region highlighted 
indicates varying levels of the peaks of interest. 
 Mar. Drugs 2012, 10                 
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2.7. Increase in Production and Biological Evaluation of Compounds 
Using the optimal growth conditions established, two large-scale cultures were grown; one 
supplemented with the HDAC inhibitor, and the other, an unmodified control culture. The cultures were 
grown, extracted and processed side-by-side, in an identical manner, and yielded similar final masses 
(3.21 g for the modified culture and 2.94 g for the control). Each culture extract was purified first by 
MPLC, then cytosporone containing fractions subject to HPLC purification. Cytosporones B (1), C (2) 
and E (3) were the major components in both cultures. However, concentrations were considerably 
enhanced in the HDAC-inhibited fermentation (Table 2).  
Table 2. Yield of Cytosporones from 10 L modified and control cultures. 
Compound  Control (mg) HDAC Inhibited (mg) Increase (%) 
Cytosporone B (1)  2.4  8.7  330 
Cytosporone C (2) 0.7    3.9  510 
Cytosporone E (3) 3.6  32.1  820 
2.8. Chemical Analysis of Additional Isolate 
The HDAC-inhibited fermentation yielded 0.9 mg of a previously undetected cytosporone. 
Cytosporone R (4) exhibited structural features similar to those of cytosporone B (1) based on the  
1H NMR spectrum (Table 3) but the presence of additional proton signals in the δ 3.5–4.5 region, 
along with MS analysis, indicated an increase in carbon, hydrogen and oxygen count (HR ESI-MS  
m/z 391.1740, Δmmu 0.7 for C19H28O7Na). While some correlations from the 2D NMR experiments 
identified that the carbon backbone, including the aliphatic side chain, was identical to that of 
cytosporone B (see Table 2), others helped determine the configuration of the additional atoms in the 
other side chain. Specifically, the HMBC (Figure 4) correlations from H2-17 to C-18 and C-19, both 
oxygen bearing sp
3 carbons (δ 71 and 64, respectively) showed the departure from the cytosporone B 
ethyl ester moiety. In addition, the HMBC correlations from the methine H-18 to both C-17 and C-19 
but to no other carbons demonstrated that the side chain ended at C-19 as a methylene with a hydroxyl 
group. Finally, using the molecular formula determined by HRMS, all that remained was an oxygen 
and hydrogen, indicating that C-18 bore a hydroxyl group as well. Cytosporone R lacked optical 
rotation, leading us to believe it is enantiomeric at C18 and thus racemic. Cytosporone R was subjected 
to bioassays against MRSA but found inactive (MIC 503 µM). These experiments cannot clarify 
whether cytosporone R arose as a response to epigenetic signaling or merely increased sufficiently 
under epigenetic control to be detected, but nonetheless highlight the utility of the method for drug 
discovery studies. 
Table 3. 
1H and 
13C NMR spectral data for cytosporone R (4) 
a and cytosporone B (1). 
Cytosporone R  Cytosporone B 
Position  δC, mult 
b  δH (mult, J in Hz)  HMBC  Position  δC  δH 
1  173.5, C    2, 17  1  171.6   
2 40.5,  CH2 3.61,  s  4  2  40.1  3.67 
3 137.1,  C    2  3 137.0   Mar. Drugs 2012, 10                 
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Table 3. Cont. 
Cytosporone R  Cytosporone B 
Position  δC, mult 
b  δH (mult, J in Hz)  HMBC  Position  δC  δH 
4  112.0, CH  6.22, d (2.2)  2, 6  4  102.5
c 6.37 
5  161.6, C    4, 6  5  160.7   
6  102.8, CH  6.27, d (2.2)  4  6  111.8
c 6.31 
7 160.0,  C    6  7 159.7   
8  121.1, C    4, 6  8  120.8   
9  209.1, C    10, 11  9  206.3   
10 45.2,  CH2  2.87, m  11, 12, 13  10  44.4  2.90 
11 25.6,  CH2  1.60, br, m  10, 12, 13  11  25.0  1.63 
12 30.5,  CH2  1.25–1.36, br, m  10, 11, 13, 14  12  30.0  1.26–1.32 
13 30.3,  CH2  1.25–1.36, br, m  11, 12, 14, 15  13  29.9  1.26–1.32 
14 32.9,  CH2  1.25–1.36, br, m  12, 13, 15, 16  14  32.5  1.26–1.32 
15 23.7,  CH2  1.25–1.36, br, m  13, 14, 16  15  23.3  1.26–1.32 
16 14.4,  CH3  0.90, t  14, 15  16  14.3  0.88 
17 66.8,  CH2  4.16, dd (11.3, 5.4)  18, 19  17  61.0  4.08 
    4.08, dd (11.3, 5.4)  18, 19       
18  71.1, CH  3.84, quin (5.4)  17, 19  18  14.5   
19 64.1,  CH2 3.54,  m  17,  18       
a 500 MHz, CD3OD; 
b Carbon multiplicity, determined by HSQC; 
c Literature values in acetone-d6 [13]. 
Original publication incorrectly assigned these carbon signals. Shown as they should be, reversed, 
as described in later publication [19]. 
Figure 4. Key HMBC correlations leading to the identification of cytosporone R (4). 
 
3. Experimental Section  
3.1. General Experimental Procedures 
Optical rotations were measured on a Rudolph Research Analytical AUTOPOL IV digital 
polarimeter. IR and UV spectra were measured on Nicolete Avatar 320FT infrared and Hewlett-Packard 
8452A diode array instruments, respectively. Medium pressure liquid chromatography was carried out on 
a Teledyne Isco Combiflash Companion using normal and reverse phase silica Gel and C18 cartridges, 
respectively, purchased from Teledyne Isco. High performance liquid chromatography was carried out Mar. Drugs 2012, 10                 
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on semipreparative Phenomenex Luna C18(2) reverse phase (250 × 10 mm) and analytical (250 × 4.6 mm) 
columns using a LC-20A Shimadzu multi-solvent delivery system, a CBM-20A Shimadzu system 
controller, and a SPD-M20A Shimadzu PDA detector. Low resolution mass spectra were recorded on an 
Agilent Technologies LC/MSD VL electrospray ionization mass spectrometer. High resolution mass 
spectra were recorded on an Agilent Technologies LC/MSD TOF electrospray ionization spectrometer. 
1H and 
13C NMR spectra were recorded on a Varian Inova instrument operating at 500 MHz for 
1H,  
125 MHz for 
13C, using residual protonated solvent as 
1H internal standard or 
13C absorption lines of 
solvents for 
13C internal standard. 
3.2. Biological Material 
A collecting trip into the mangroves of the Florida Everglades was conducted in the summer of 2010. 
All samples were processed and collected “in-place”, within the guidelines of the State of Florida 
Department of Environmental Protection, taking precautions from harming these ecologically important 
trees. To remove epiphytes, a portion of a branch was first treated with 30% sodium hypochlorite for 
30 s, rinsed thoroughly with sterile water, then treated with 70% isopropanol for 30 s and finally rinsed 
with sterile water. Shavings of the bark (each less than 2 mm in length, width or thickness) from the 
surface-sterilized branch were placed onto a Petri dish containing cornmeal agar made with autoclaved 
seawater. This was incubated at room temperature for 3 weeks, monitoring the growth of microbes each 
day. Single filaments of fungi were removed and re-plated repeatedly until pure colonies were obtained. 
3.3. DNA Extraction 
The fungus was grown on a plate of SDA for 7 days. An area of 1 cm
2 of the fungal mat was cut 
and placed into a 1.5 mL Eppendorf tube with 600 µL of PBS buffer and about 0.5 cm of 0.1 mm glass 
disruption beads. The tube was placed into a bead beater and pulsed for 1 m, three times, to lyse the 
cells. The tubes were centrifuged and the supernatant removed to a clean microfuge snap-cap tube.  
200 µL of 1.6% sarkosyl and 25 µg of proteinase K were added, and incubated at 60 °C for 60 m. 
After incubation, 800 µL of phenol/chloroform was added and the samples vortexed. The resulting 
emulsion was centrifuged for 5 m and the aqueous layer was removed and placed into a new tube.  
500 µL of isopropanol and 100 µL of 3 M sodium acetate were then added to tubes before being 
mixed. Tubes were then placed at −80 °C for 2 h to allow DNA precipitation. The sample tube was 
then vortexed for 5 m and the supernatant was discarded. The DNA pellet was washed with 500 µL of 
70% ethanol and resuspended in DI water in a refrigerator overnight. 
3.4. PCR Parameters 
DNA from the fungus was amplified in two PCR mixtures containing the following total amounts:  
2 µL of DNA, 12.5 µL Taq DNA Polymerase, 6.5 µL of DI water, 2 µL of forward primer nu-SSU-
0817-5′ (TTAGCATGGA ATAATRRAATAGGA) and either 2 µL of reverse primer nu-SSU-1196-3′ 
(TCTGGACCTGGTGAGTTTCC) or nu-SSU-1536-3′ (ATTGCAATGCYCTATCCCCA) [20]. All 
reagents were combined and heated at 94 °C for 2.5 m. Thirty-five cycles of PCR were then performed 
by using 94 °C for 0 s, 56 °C for 10 s, and 72 °C for 30 s, followed by 72 °C for 2.5 m. Mar. Drugs 2012, 10                 
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3.5. Gel Step and Isolation of DNA 
1% agarose gel was poured into a gel caster with 10 µL of 10 mg/mL solution of ethidium bromide. 
When solid, it was placed into a gel electrophoresis apparatus filled with TAE buffer (a mixture of Tris 
base, acetic acid and EDTA). 25 µL of the PCR sample mixtures were added to wells alongside 25 µL 
of a 1 kb DNA ladder. Samples were then run at 80 volts and 400 mA for 30 m. The resulting gel was 
viewed under a UV lamp and the portions containing DNA were removed using a surgical blade. The 
DNA was then isolated and purified using a QIAquick Gel Extraction kit. 
3.6. Fungus Identification 
The DNA was sent to Eurofins MWG Operon for sequencing. Upon receiving the results, they were 
compared to the BLAST database and the fungus was found to be 99% identical to Leucostoma persoonii. 
3.7. Initial Culture and Screening 
The fungi isolated from the expedition were each grown onto two Petri dishes containing SDA at  
30 °C for 3 weeks. The resulting cultures were freeze-dried and extracted in methanol. The resulting 
crude extracts were concentrated, and each was diluted to an approximate concentration of 30 mg/mL 
in DMSO. The samples were then submitted for screening. 
3.8. Malaria Assay 
Malaria screening was done as previously reported [21]. 
3.9. Methicillin-Resistant Staphylococcus Aureus Strain 
The strain of MRSA used in our bioassays is a hospital-associated clone from the CDC USA 100 
lineage. It was isolated from Tampa General Hospital and was found to be broadly resistant to a variety 
of antimicrobials, including: methicillin, centhromycin, azithromycin, erythromycin, clindamycin, 
ampicillin, chloramphenicol, gentamicin, tetracycline, ciprofloxacin; as well as intermediary resistance to 
daptomycin, linezolid and vancomycin. It is thus deemed an extensively drug resistant strain, and 
something of a worst-case scenario MRSA isolate. 
3.10. Disk Diffusion Assay 
Assays for crude extracts and fractions were performed as described previously [22].  
3.11. Natural Product Extraction and Isolation 
For the isolation of bioactive natural products, the fungus was grown following the optimal epigenetic 
modifier conditions identified previously at the larger scale of 10 L. The lyophilized fungus was 
extracted three times with MeOH. The extract was concentrated to yield a mass of 3.21 g. The residue 
was subjected to reverse phase MPLC using a gradient (10% MeOH in purified water to 100% MeOH) 
to give 8 fractions: A (942 mg), B (317 mg), C (209 mg), D (158 mg), E (442 mg), F (268 mg), G (94 mg) Mar. Drugs 2012, 10                 
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and H (85 mg). These fractions were screened against MRSA and fraction E was found to be active 
with a ZOI of 20 mm. It was further separated using normal phase MPLC using a gradient (100% 
hexanes to 100% ethyl acetate, then to 100% methanol) to give 16 fractions: A (9 mg), B (96 mg),  
C (21 mg), D (25 mg), E (13.4 mg), F (20 mg), G (13 mg), H (15 mg), I (24 mg), J (35 mg), K (40 mg), 
L (32 mg), M (72 mg), N (31 mg), O (53 mg), P (103 mg). The fractions were once again tested against 
MRSA and the active fraction, B, was further separated on reverse phase HPLC using a gradient (20% 
acetonitrile in purified water to 100% acetonitrile) to afford pure cytosporones in the chromatographic 
sequence of R (4) E (1), C (3) and B (2). 
1H and 
13C NMR spectra of cytosporones B, C and E matched 
literature values [14]. 
3.12. Microtiter MIC and MBC Determination Assays 
The minimum inhibitory concentration (MIC) of the pure compounds was determined as follows. 
Broth cultures were prepared for S. aureus strains as described above. These were diluted 1:1000 in fresh 
Trypticase Soy Broth (TSB) and 200 µL was applied to the wells of a sterile 96-well plate. Compounds 
(in DMSO) were added to wells at concentrations ranging from 1, 10, 25, 50 to 100 µg/mL in a volume 
no greater than 5 µL. Concentrations were adjusted to lower levels if applicable. Samples were mixed 
by pipetting and the plates were incubated at 37 °C overnight. MICs were determined by visual 
inspection for the minimum concentration of compound producing no bacterial growth, as determined by 
a lack of turbidity. Assays were repeated three times in order to verify the MIC determinations. Negative 
controls performed with DMSO alone revealed no inhibition to bacterial growth. As a positive control, 
vancomycin was used and was found to have an MIC of 1 µg/mL. Minimum bactericidal concentration 
(MBC) counts were performed on the MIC cultures by removing the growth media from each well the 
following morning, serially diluting, and plating onto Trypticase Soy Agar (TSA). These were incubated 
overnight at 37 °C and the bacterial loads of each well were determined by enumeration. Percentage 
killing was determined by the comparison of drug-containing wells to control wells where no compound 
was added. 
3.13. Biofilm Assay 
We performed minimum biofilm eradication count (MBEC) assays on cytosporones to assess their 
activity towards this form of bacterial growth. These were performed by generating S. aureus biofilms 
in a 96-well microtitre plate, as previously described [23]. Once established, biofilm cultures were 
exposed to fresh growth media containing a range of concentrations of 15, 20, 25 and 50 µg/mL of the 
cytosporones. Control analyses were performed in parallel containing no compound. Cultures were 
incubated, covered, for 24 h at 37 °C without shaking. After this time the culture media was aseptically 
aspirated, and the wells rinsed twice with PBS to remove non-adherent cells. Fresh PBS (100 µL) was 
then added to the wells, and mixed by vigorous pipetting, to dislodge the biofilm matrix from the surface 
of the wells. These samples were serially diluted, plated on TSA, with cells enumerated after overnight 
incubation at 37 °C. Each of the above analyses was performed with 3 biological replicates, each of 
which also had 3 technical replicates. By comparing CFU/mL against control, no-exposed cultures, we 
were able to obtain a quantitative assessment of the impact of cytosporones on S. aureus biofilms. 
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3.14. Cytotoxicity Assay 
Cell line A549 (adenocarcinomic human alveolar epithelial cells) was cultured in F-12K Nutrient 
Mixture (Kaighn’s Modification) media containing L-glutamine, supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin. For the assay, the A549 cells were diluted to 1.33 × 10
5 cells/mL 
in DMEM F12 media with L-glutamine, without HEPES or phenol red, and supplemented with 2% 
fetal bovine serum and 1% penicillin-streptomycin. The A549 cells were dispensed into 96 well plates 
at a volume of 90 µL/well giving a final concentration of 12,000 cells per well. Plates were incubated 
for 24 h at 37 °C and 5% CO2. After 24 h, 10 µL of the test compounds at concentrations of 0.4, 1.2, 
3.7, 11, 33.3 and 100 µg/mL were added to the 96 well plates containing A549 cells followed by 72 h 
of incubation at 37 °C and 5% CO2. A Beckman-Coulter Biomek NX 3000 was used to dispense cells 
and dispense test compounds to the 96 well plates. Positive (bronopol) and negative (blank DMSO) 
controls were included on each assay plate. After the incubation period, cell proliferation was assessed 
using Promega’s CellTiter 96 Aqueous One Solution Cell Proliferation Assay reagent. Into each well 
20 µL of reagent was added followed by incubation for 3 h at 37 °C and 5% CO2. A Biotek plate 
reader was used to read absorbance at 490 nM and IC50 values were determined for each test 
compound. 
3.15. Epigenetics Studies 
The fungus was subjected to a series of epigenetic modification experiments, including types of 
modifiers (5-azacytidine as a DNA methyltransferase (DNMT) inhibitor and sodium butyrate as a 
histone deacetylase (HDAC), or a combination of the two), a modifier concentration gradient of 1,  
10, 50, 100 and 500 µM, and a time course (1, 2 and 3 weeks). Culture experiments were performed in 
triplicate. Plugs of agar containing mycelia from small-scale solid phase cultures of the fungus were 
placed into vessels containing 125 mL of sterile SDB. The vessels were then placed on a rotary shaker 
at 20 rpm for 48 h at room temperature. Then an aliquot of the epigenetic modifier was added to reach 
appropriate final concentrations of 1–500 µM, to achieve desired dose-response concentrations. After 
modifier treatment, vessels were shaken for an additional 5–19 days, to achieve the desired time 
course. The resulting cultures were lyophilized and extracted in MeOH. All biological assays and 
chemical experiments for the epigenetic experiments were performed with these extracts. 
3.6. Cytosporone R (4) 
Colorless oil; [α]
25
D +0 (c 0.1, MeOH); UV/Vis (MeOH) λmax (ε): 269 (802), 297 (609); IR (thin 
film): 3237, 2928, 2855, 1706, 1589, 1467, 1371, 1331, 1269, 1241, 1165, 1111 cm
−1; HRESIMS  
m/z [M + Na]
+ 391.1740 (C19H28O7Na calculated 391.1733); 
1H and 
13C NMR, see Table 3. 
4. Conclusions  
Cytosporone E (3) displays modest potency against both the highly resistant USA100 strain of 
MRSA, as well as Plasmodium falciparum, with sufficiently low mammalian cytotoxicity to provide  
a therapeutic index >10 for both infectious diseases. Epigenetic modification of fungal cultures Mar. Drugs 2012, 10                 
 
773
demonstrated noteworthy utility in this case, increasing drug titers significantly and providing access 
to new chemodiversity.  
Acknowledgments 
We thank undergraduate researchers S. Austin, F. Co and E. Herrera for field collection and lab 
work assistance, K. Seely for HRMS data, H. Miller and F. Rivera for training in DNA isolation  
and purification. This research was supported in part by Medicines for Malaria Ventures Grant 
MMV08/0105 and in part by Grant 1R01AI080626-01A2 (LNS) from the National Institute of 
Allergies and Infectious Diseases.  
References 
1.  Mumby, P.J.; Edwards, A.J.; Arias-González, J.E.; Lindeman, K.C.; Blackwell, P.G.; Gall, A.; 
Gorczynska, M.I.; Harborne, A.R.; Pescod, C.L.; Renken, H.; et al. Mangroves enhance the 
biomass of coral reef fish communities in the Caribbean. Nature 2004, 427, 533–536. 
2.  Liu, D.; Li, X.M.; Meng, L.; Li, C.S.; Gao, S.S.; Shang, Z.; Proksch, P.; Huang, C.G.; Wang, B.G. 
Asperolides A–C, tetranorlabdane diterpenoids from the marine alga-derived endophytic fungus 
Aspergillus wentii EN-48. J. Nat. Prod. 2011, 74, 1787–1791. 
3.  Cao, S.; Clardy, J. New naphthoquinones and a new delta-lactone produced by endophytic fungi 
from Costa Rica. Tetrahedron Lett. 2011, 52, 2206–2208.  
4.  Huang, H.; Feng, X.; Xiao, Z.; Liu, L.; Li, H.; Ma, L.; Lu, Y.; Ju, J.; She, Z.; Lin, Y. Azaphilones 
and p-terphenyls from the mangrove endophytic fungus Penicillium chermesinum (ZH4-E2) isolated 
from the South China Sea. J. Nat. Prod. 2011, 74, 997–1002. 
5.  Crawford, J.M.; Clardy, J. Bacterial symbionts and natural products. Chem. Commun. 2011, 47, 
7559–7566. 
6.  Cai, S.; Sun, S.; Zhou, H.; Kong, X.; Zhu, T.; Li, D.; Gu, Q. Prenylated polyhydroxy-p-terphenyls 
from Aspergillus taichungensis ZHN-7-07. J. Nat. Prod. 2011, 74, 1106–1110. 
7.  Cao, S.; Ross, L.; Tamayo, G.; Clardy, J. Asterogynins: Secondary metabolites from a costa rican 
endophytic fungus. Org. Lett. 2010, 12, 4661–4663. 
8.  Lu, Z.; Zhu, H.; Fu, P.; Wang, Y.; Zhang, Z.; Lin, H.; Liu, P.; Zhuang, Y.; Hong, K.; Zhu, W. 
Cytotoxic polyphenols from the marine-derived fungus Penicillium expansum. J. Nat. Prod. 2010, 
73, 911–914. 
9.  Wen, L.; Cai, X.; Xu, F.; She, Z.; Chan, W.L.; Vrijmoed, L.L.P.; Jones, E.B.G.; Lin, Y. Three 
metabolites from the mangrove endophytic fungus Sporothrix sp. (#4335) from the South China 
Sea. J. Org. Chem. 2009, 74, 1093–1098. 
10.  Vervoort, H.C.; Draskovic, M.; Crews, P. Azonazine, a novel dipeptide from a hawaiian marine 
sediment-derived fungus, Aspergillus insulicola. Org. Lett. 2011, 13, 410–413. 
11.  Wang, X.; Filho, J.G.S.; Hoover, A.R.; King, J.B.; Ellis, T.K.; Powell, D.R.; Cichewicz, R.H. 
Chemical epigenetics alters the secondary metabolite composition of guttate excreted by an 
Atlantic-Forest-derived Penicillium citreonigrum. J. Nat. Prod. 2010, 73, 942–948. 
12.  Scherlach, K.; Hertweck, C. Triggering cryptic natural product biosynthesis in microorganisms. 
Org. Biomol. Chem. 2009, 7, 1753–1760. Mar. Drugs 2012, 10                 
 
774
13.  Schwab, E.K.; Bok, J.W.; Tribus, M.; Galehr, J.; Graessle, S.; Keller, N.P. Histone deacetylase 
activity regulates chemical diversity in Aspergillus. Eukaryot. Cell 2007, 6, 1656–1664. 
14.  Brady, S.F.; Wagenaar, M.M.; Singh, M.P.; Janso, J.E.; Clardy, J. The cytosporones, new octaketide 
antibiotics isolated from an endophytic fungus. Org. Lett. 2000, 2, 4043–4046. 
15. Paranagama, P.A.; Wijeratne, E.M.; Gunatilaka, A.A. Uncovering biosynthetic potential of   
plant-associated fungi: Effect of culture conditions on metabolite production by Paraphaeosphaeria 
quadriseptata and Chaetomium chiversii. J. Nat. Prod. 2007, 70, 1939–1945. 
16.  Xu, J.; Kjer, J.; Sendker, J.; Wray, V.; Guan, H.; Edrada, R.; Müller, W.E.; Bayer, M.; Lin, W.; 
Wu, J.; Proksch, P. Cytosporones, coumarins, and an alkaloid from the endophytic fungus 
Pestalotiopsis sp. isolated from the Chinese mangrove plant Rhizophoramucronata. Bioorg. Med. 
Chem. 2009, 17, 7362–7367. 
17. Abrei, L.M.; Phipps, R.K.; Pfenning, L.H.; Gotfredsen, C.H.; Takahashi, J.A.; Larsen, T.O. 
ChemInform abstract: Cytosporones O (I), P (IIa) and Q (IIb) from an endophytic Cytospora sp. 
Tetrahedron Lett. 2010, 41, 1803–1805. 
18.  Trager, W.; Jenson, J.B. Cultivation of malarial parasites. Nature 1978, 273, 621–622. 
19.  Zhan, Y.; Du, X.; Chen, H.; Liu, J.; Zhao, B.; Huang, D.; Li, G.; Xu, Q.; Zhang, M.; Weimer, B.C.; 
et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat. Chem. Biol. 2008, 4, 
548–556. 
20.  Borneman, J.; Hartin, R.J. PCR primers that amplify fungal rRNA genes from environmental samples. 
Appl. Environ. Microbiol. 2000, 66, 4356–4360. 
21.  Lebar, M.D.; Hahn, K.N.; Mutka, T.; Maignan, P.; van Olphen, A.; Kyle, D.E.; McClintock, J.B.; 
Amsler, C.D.; Baker, B.J. CNS and antimalarial activity of synthetic meridianin and psammopemmin 
analogs. Bioorg. Med. Chem. 2011, 19, 5756–5762. 
22.  Burda, W.N.; Fields, K.B.; Gill, J.B.; Burt, R.; Shepherd, M.; Zhang, X.P.; Shaw, L.N. Neutral 
metallated and meso-substituted porphyrins as antimicrobial agents against gram-positive pathogens. 
Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 327–335. 
23.  Beenken, K.E.; Blevins, J.S.; Smeltzer, M.S. Mutation of sarA in Staphylococcus aureus limits 
biofilm formation. Infect. Immun. 2003, 71, 4206–4211. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 